Gene Therapy Development & Manufacturing 2023 delivers in-depth discussion on optimised process strategies and technologies for the successful technical development and manufacture of advanced gene therapy products.
Bringing together leading omics experts from around the world and comprised of three outstanding programmes, delegates can expect to benefit from critical discussions in the future of Next Generation Sequencing, Multi-omic Single Cell & Spatial Analyses and Genome editing in Drug Discovery and Therapeutic Development.
The 2023 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.
Below are some of the confirmed speakers of NextGen Omics US 2023.
Timothy Dahlem, Director of Systems Biology at Recursion Pharmaceuticals
Kamel Khalili, Laura H. Carnell Professor and Chair Lewis Katz School of Medicine at Temple University
Kalina Hristova, Professor of Materials Science and Engineering Institute for NanoBioTechnology at John Hopkins University
Guo-Cheng Yuan, Professor of Computational Biology at Icahn School of Medicine at Mount Sinai
Tirtha Chakraborty, Chief Scientific Officer at Vor Biopharma
Sandra Smieszek, Head of Genetics at Vanda Pharmaceuticals
An innovative 2 day meeting brings together a panel of over 150 prominent leaders and scientists, exploring Sustainable Chemistry, aiming to innovate processes to improve product performance whilst delivering environmental benefits.
Discuss the latest advancements in innovative approaches to sustainable drug development and manufacturing process.
Engage in scientific discussions paving the way towards sustainable chemical synthesis, analytical chemistry and chemical process development.
Dive into the latest technologies driving down pharma sector emissions by implementing “green-by-design” in early drug development phase pipeline projects.
Gain a comprehensive understanding of the peptides and oligonucleotides sustainability landscape; key sessions include application and technology areas.
Join a series of workshops, roundtables, and panel discussions to collaborate with your peers. 2023 sessions include: Greener Peptides, Green Chemical Synthesis, Chemistry in Water, Green Medicinal Chemistry and Green Manufacturing
Engage with esteemed pharmaceutical & biotech representatives as well as thought-leaders from academic & research institutions onsite and benefit from attending over 60 presentations. We will be welcoming onsite over 300 delegates for two days of cutting-edge scientific sessions and case studies bringing the latest biologics developments to the forefront of research
A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.
Biomarkers 2023, designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.
It includes over 90 cutting-edge presentations and discussion sessions, 8+ hours of valuable networking sessions and an exhibition hall showcasing 50+ vendor companies.
The EBRC Student and Postdoc Association is hosting a Data and Engineering Biology: Operating at the Technical Interface panel event, where researchers can connect with professionals who operate and lead within ‘data-centric’ bioengineering companies.
Panelists will discuss 1) transitioning from their PhD to industry, 2) details about their current role, and 3) which data-specific skills are valued in their organization. The discussion will also cover how lab automation, data science, or DevOps platforms drive overall biology objectives at their companies. Join us virtually on December 6th, 2022 (2-3pm ET |11-12pm PT) on GatherTown by registering here.
Click here to view our flyer.
Please contact Eric South (esouth@bu.edu) if you have any questions.
Diana Koulechova, Ph.D.
LinkedIn
Diana is a Senior Scientist at Tierra Biosciences, where she works to improve and expand their cell-free protein synthesis platform, affecting their internal slogan of “Proteins for All.” Prior to joining Tierra, she developed processes and methods in biologics downstream development at the immunoncology company Agenus, and also prototyped a continuous processing system for biologics manufacturing at the pharmaceutical company Boehringer Ingelheim. She received her PhD in Molecular and Cell Biology from University of California, Berkeley and has been in a variety of biochemistry fields ranging from homing endonucleases, protein folding, and somatosensation in C. elegans.
Ben Gordon, Ph.D.
LinkedIn
Ben is a Senior Director of Research at Asimov Inc. and a Director at the MIT / Broad Synthetic Biology Foundry. He has extensive experience in both managing and leading teams in computer-aided synthetic biology. Ben received a Ph.D. in Computational Biophysical Chemistry from Caltech, where he conducted work on computational protein design and engineering. He later became a Postdoctoral Associate at the Whitehead Institute and then a Principal Scientist and Strategic Collaborations Manager at Agilent Technologies. Ben is also a Program Manager at BioMADE – a Bioindustrial Manufacturing Innovation Institute.
Naomi Handly, Ph.D.
LinkedIn
Naomi is a quantitative cell biologist by training. At Octant, she’s had several roles including recruiting, establishing the OA program, building Octant HQ, demonstrating Octant’s multiplexed platform technology, building cell engineering, and more. Naomi received her PhD from the University of California, San Diego under Roy Wollman quantifying how cells communicate with one another to determine their position in relation to a wound. She’s passionate about bringing science to the public through effective scientific communication and meaningful technological advances.
Marilene Pavan, Ph.D.
LinkedIn
Marilene is a High-Throughput Synthetic Biology Manager at LanzaTech Inc., a carbon recycling technology company, specialized in converting waste carbon oxides into biofuels and chemicals. She is a Biologist with 15+ years of experience in the fields of synthetic biology, metabolic engineering, and biomanufacturing, with previous experience working for chemical industries like Braskem S/A and leading biotech companies as Monsanto S/A, She moved to the US in 2016 to work as Research Fellow at Boston University, later joining Lanzatech in 2019. Her expertise also includes partnerships (prospection and management); people management and mentorship; fundraising; business development; grant, patent, and scientific article writing; project evaluation and management; budget management; scientific consulting; and conference planning and speaking. She holds a master’s degree in Molecular Biology and is also specialized in Strategic Management of Technological Innovation. She is currently a Ph.D. Candidate in the Bioenergy Program of the University of Campinas, UNICAMP – Brazil.
This is an invitation-only event.
Register here
The second EBRC Global Forum for Engineering Biology: Review of Synthetic Biology/Bioeconomy National Strategies (EBRC Global Forum 2.0) will be held on the 20th and 21st of February 2023 in Singapore in partnership with the Singapore Consortium for Synthetic Biology (SINERGY). The Forum will bring together a group of global leaders for an international summit focused on national synthetic biology roadmaps and bioeconomy strategies. Our goal is to facilitate presentations and discussions among leading representatives in the field in a relaxed, not-for-attribution forum.
The two-day agenda will include:
Participants are expected to cover their own travel and accommodation expenses. We will facilitate room blocks and/or make recommendations for accommodation, but we will not be covering the costs. We have some limited ability, on a case-by-case basis, to fund travel for those who could not otherwise participate without travel funding assistance.
We are pleased to announce our new conference on synthetic biology. This conference will present how technologies from synthetic biology are delivering innovations across clinical health applications and leading towards improved global health.
The meeting will bring together researchers working on synthetic biology, biotechnology, genomics and medical sciences, along with industry members from pharma and biotech companies, and investors and funders in this growing research area. It will address how the technologies coming out of synthetic biology impact both advanced healthcare in developed countries (e.g. personalised medicines, T-cell therapies) and global wide-impact, such as very low-cost diagnostics and self-replicating living therapies. In addition, the conference aims to provide a reflection on where resources and work are succeeding and where more effort needs to be placed to ensure equitable global outcomes.
We aim to organise this meeting as a hybrid conference – with on-site or virtual attendance. If you would like to be part of these discussions – consider submitting an abstract by 17 January 2023 and register by 14 February (in-person) or 6 March (virtual) 2023.
To promote more inclusive scientific discussions with international colleagues at our conferences, virtual delegates based in Lower and Middle-Income Countries can register for free.
GOGEC, a virtual conference, allows students to present their work and meet other synthetic biology students around the world without having to worry about registration fees. Projects can include any sort of synthetic biology work including engineering organisms, purely computational or software work, or building non-biological devices with biological applications. You can find more information and register here.
Join local, state, and national leaders in education, government, and industry on October 27th, 2022 as we build a better and more sustainable future in the Appalachian Highlands. Stakeholders will gather at East Tennessee State University to pair local expertise in manufacturing, fermentation, and agriculture with global innovations in life science. This event will establish collaborations and partnerships to shape a world-class bioeconomy in the region. Featured speakers include EBRC members Natalie Kuldell (BioBuilder) and Tom Tubon (BioMADE). The symposium is free and open to the public, but you must register to attend. You can learn more and register here.
Reminder to EBRC Council members in industry, government, and academia, to register and book your travel for the EBRC 2022 Council Meeting at J. Craig Venter Institute, in La Jolla, CA on November 7-8, 2022.
Travel Support and Meeting Hotel:
We anticipate covering airfare and hotel expenses for EBRC Academic Council Members. Please see EBRC’s full travel policy here.
EBRC has reserved a block of hotel rooms at the Embassy Suites by Hilton San Diego La Jolla at 4550 La Jolla Village Dr, San Diego, CA 92122 at $189.00 per night. Please indicate on the registration page if you will need hotel accommodations. We will reserve the room in our block. If your travel is not covered by EBRC, you can provide payment at check in. Please contact helix@ebrc.org with any questions rather than contacting the hotel directly.
Health and Safety:
We are committed to hosting a safe event. We will be closely watching CDC recommendations in addition to all relevant local and state guidelines leading up to the Meeting and make any changes necessary for health and safety. Proof of vaccination will be required for attendance. A rapid antigen testing strategy may also be deployed depending on conditions. Meals will be provided outside.
The iGEM Grand Jamboree is where the future of synthetic biology is showcased every year. This year, 350+ multidisciplinary teams from 40+ countries will be presenting their projects on how to solve local problems, all over the world, using synthetic biology.
The iGEM Grand Jamboree is home of the world’s largest SynBio community of researchers, industry, investors, startups and policy makers.
After 15 years in Boston and 2 years remotely, iGEM chose the most beautiful city in the world and its Parc des Expositions, the largest venue in Europe and just 15 min away from the Eiffel Tower, to host the most important gathering for synthetic biology. Learn more and register here.
Our 3D Cell Culture congress incorporates key trends and innovative technologies to accelerate the adoption of 3D models in preclinical research via advanced development, validation and application strategies.
An intensive 1-day meeting that delves into the latest in oligonucleotides chemistry, process & analytical development, therapeutics, antisense therapy & a meeting place for experts working within cutting-edge oligo research & therapeutic development.
Join the 2022 Precision Medicine World Conference on June 28-30,2022 located at the Santa Clara Convention Center! The program will include:
EBRC’s Dr. India Hook-Barnard will present at PMWC 2022. India will chair the UC Precision Medicine Programs: Achievements and Challenges session on June 28.
PMWC is the largest & original annual conference dedicated to precision medicine, bringing together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization & collaboration in an effort to accelerate the development and spread of precision medicine. Click here for more information.
The 2022 ASBMB Annual Meeting, held in conjunction with Experimental Biology, will take place in person April 2–5 in Philadelphia.
About EB
The Experimental Biology conference — hosted by five scientific societies supporting studies in biochemistry and molecular biology, anatomy, pharmacology, physiology and pathology — attracts thousands of researchers and exhibitors.
Starting in 2023, the five societies will be parting ways. So don’t miss this last chance to converse and forge collaborations with scientists from multiple disciplines with shared research interests.
For more information and to register, click here.
Wednesday, April 6th, 2022
12:00pm-3:00pm ET | 9:00am-12:00pm PT
Register here
Registration closes April 4th, 2021
Agenda: Coming Soon!
This virtual workshop will focus on filling in technical gaps and move us closer to completing the technical content of the Roadmap. Participants will review the identified technical gaps and fill in those gaps by drafting technical milestones, bottlenecks, and potential solutions.
This is anticipated to be the last technical writing workshop for the EBRC Climate & Sustainability Roadmap before we start the review and revision phase of the roadmapping process.
This workshop is open to participation from all stakeholders.
For more information about the roadmap or workshop, please contact Sifang Chen (schen@ebrc.org)
This workshop is by invitation only, with a limited number of attendants. The workshop will focus on reviewing and revising our technical research roadmap to advance engineering biology tools and technologies that respond to the urgency of the climate crisis and promote long-term sustainability.
Register here
April 11th, 2022: Registration closes; Deadline for hotel and travel arrangements by EBRC
Agenda Outline
Detailed Agenda Coming Soon!
Workshop Objectives
Review Technical Themes, Research Goals, and Milestones collectively and holistically to identify gaps and summarize the priorities, potential impacts, and the messages they portray.
Participants will work independently and in small groups to review, revise, and complete the content of the technical roadmap.
Identify Milestones in need of further discussion and revise identified Milestones based on the discussions.
Group review and discussion of case studies on Social and Non-Technical Considerations.
Travel Support and Meeting Hotel:
We anticipate covering travel expenses for academics, including students and postdocs. Please see EBRC’s full travel policy here.
We will be reserving a block of rooms at DoubleTree Hilton in Skokie, IL at a rate of $119/night. Please indicate on the registration page if you will need hotel accommodations. If your travel is not covered by EBRC, you can provide payment at check in. Please contact helix@ebrc.org with any questions rather than contacting the hotel directly.
Health and Safety:
We are committed to hosting a safe event. We will be closely watching CDC recommendations in addition to all relevant local and state guidelines leading up to the workshop and make any changes necessary for health and safety. Proof of vaccination will be required for attendance. A rapid antigen testing strategy may also be deployed depending on conditions.
For more information about the roadmap or workshop, please contact Sifang Chen (schen@ebrc.org)
For information on EBRC’s travel policies, please contact helix@ebrc.org.
The EBRC Student and Postdoc Association is hosting a Transitioning to Business Roles Post-PhD panel event, where researchers can connect with professionals who work in venture capital, consulting, business development, and technology transfer following a biotech graduate education. Join us virtually on April 6th, 2022 (2:00-3:30pm ET |11:00-12:30am PT) on GatherTown by registering here. Our diverse panel includes a broad range of business perspectives that will provide insights on how graduate students can begin to differentiate in preparation for these career paths.
Click here to view our flyer.
Please contact Eric South (esouth@bu.edu) if you have any questions.
Sarah R. Carter, Ph.D.
LinkedIn
Dr. Carter is the Principal at Science Policy Consulting LLC where she focuses on societal and policy implications of emerging biotechnologies. Trained as a scientist, she has a detailed understanding of synthetic biology and tracks advances in biotechnology as they arise. She has 10+ years of experience working with policy frameworks related to biotechnologies and the increasingly diverse biotechnology industry, and has contributed to many policy projects and processes, including those organized by U.S. government agencies, non-profit and academic institutions, and others. Previously, she worked in the Policy Center of the J. Craig Venter Institute and in the Obama Administration’s White House Office of Science and Technology Policy (OSTP). Dr. Carter is a former AAAS Science and Technology Policy Fellow and a former Mirzayan Fellow of the National Academies. She earned her Ph.D. in Neuroscience from the University of California-San Francisco and her bachelor’s degree in Biology from Duke University.
Travis D’Cruz, Ph.D., MSEM
LinkedIn
Dr. D’Cruz is a Senior Manager at Oncorus with an advanced background in life sciences research and several years of experience in facilitating technology commercialization. Travis is adept at spearheading partnership discussions to execute productive deals, along with experience in leading asset-focused partnering discussions with large pharma, supporting strategic collaborations from initial discussions through post-deal alignment, and supporting technology licensing deals to enhance company pipeline and platforms. Previously, Dr. D’Cruz led and managed all aspects of academic tech transfer for Tufts University’s life science portfolio, and assisted with patent strategy, IP licenses, routine contracts, and alliance management. Dr. D’Cruz earned a Ph.D. in Neuroscience from Penn State University, a Master of Science in Engineering Management at Tufts University, and a bachelor’s degree in Biology from Drexel University.
Eric Keen, Ph.D.
LinkedIn
Dr. Keen joined Flagship Pioneering in 2022 following completion of Flagship’s 2021 Fellows Program. As part of Geoffrey von Maltzahn’s origination team, Eric works to conceive and develop transformative bioplatform companies which address key challenges in health and sustainability. Eric holds a Ph.D. in Molecular Microbiology and Microbial Pathogenesis from Washington University in St. Louis, where he was a National Science Foundation Graduate Research Fellow, and a B.S. in Biology with highest honors from the University of Miami, where he was a Barry M. Goldwater Scholar. Outside of work, Eric enjoys hiking, biking, and almost anything else outdoors.
Anji Miller, Ph.D. CLP RTTP
LinkedIn
Dr Miller is a technology transfer professional with extensive experience of developing and translating early-stage translational research. Her current role at LifeArc involves working with academic and charitable establishments to identify, cultivate, fund, and commercialise early-stage healthcare technologies, focusing on rare diseases and advance therapies.
Prior to joining LifeArc, she worked for several leading establishments, including The Wellcome Trust and St George’s University of London, working at the forefront of academic translational research and knowledge transfer policy. A proponent for professional advancement in technology transfer, Dr Miller directs the LifeArc AUTM Tech Transfer Fellowship, a programme designed to train and assist scientists to become TT professionals, and she is the skills lead for the UK’s recently launched Innovation Hubs for Gene Therapy. An advocate of equality diversity and Inclusion, Dr Miller cofounded Global Equality, Diversity and Equality in Technology Transfer (GEDITT), an initiative missioned to raise awareness and promote EDI in the TT sector.
Dr Miller holds an M.Sc. in Human Molecular Genetics and Ph.D in Cancer Genetics from Imperial College, and M.Sc. and Certificate in IP Law from QMUL. She is a certified project manager, Registered Technology Transfer Professional and Certified Licensing Professional. Dr Miller serves as VP of Communities on the ASTP Board, a member of the BioIndustry Association (BIA) Cell & Gene Therapy Advisory Committee, and the AUTM Equity, Diversity & Inclusivity Committee.
